Close

Anti-Peptide RVL T cell receptor (BDC-10.1), pCDTCR1 (TCR-YC0952)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The BDC-2.5 and BDC-10.1 CD4 T cell clones both weakly react with the naturally occurring 358-371 cleavage product (WE14) of chromogranin A (ChgA), a bioactive peptide precursor found in the secretory vesicles of endocrine cells and neurons. The BDC-2.5 CD4 T cells also were reported to recognize a distinct hormonal polypeptide derived from ChgA, the vasostatin-1–derived peptide ChA (29–42).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide RVL
  • Epitope
  • RVLPVWVRME
  • Format
  • Non-Modified TCR
  • Allele
  • H2 class II
  • Targeting Diseases
  • Type 1 diabetes (T1D)
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • BDC-10.1
  • Host Species
  • Mouse

Target

  • Introduction
  • Multiple studies highlighted the overtly self-reactive T cell repertoire in the diabetes-prone NOD mouse. This autoreactivity has primarily been linked to defects in apoptosis induction during central tolerance. Previous studies suggested that thymus-specific serine protease (TSSP), a putative serine protease expressed by cortical thymic epithelial cells and thymic dendritic cells, may edit the repertoire of self-peptides presented by MHC class II molecules and shapes the self-reactive CD4 T cell repertoire.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide RVL T cell receptor (BDC-10.1), pCDTCR1 (TCR-YC0952). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.